Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.
Q&A: The scientific integrity sleuth taking on the widespread problem of research misconduct
Elisabeth Bik, a microbiologist by training, has become one of the world’s most influential science detectives. An authority on scientific image analysis who’s been profiled
February 28, 2024